| Expression pattern: |
UP |
| Associated gene: |
E2F3 |
| Associated microRNA: |
miR-7-5p |
| Biological function: |
Promotes NPC cell viability/proliferation and enhances glucose metabolism (glucose consumption, lactate production, ATP production); promotes xenograft tumor growth in vivo. |
| Molecular mechanism: |
Acts as a ceRNA/miRNA sponge: CDR1as binds miR-7-5p, relieving repression of E2F3 and increasing E2F3 mRNA/protein; validated by dual-luciferase assays and expression/correlation analyses; impacts tumor glycometabolism. |
| Biological pathway or process: |
ceRNA regulation (promotes); proliferation (promotes); glycolysis (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Clinical Sample Validation; Transfection; CCK8; Colony Formation Assay; Luciferase Reporter Assay; Western Blot; In Vivo Animal Model; IHC (Immunohistochemistry); Bioinformatics Analysis; Survival Analysis |
| Clinical significance: |
High CDR1as expression was associated with prognosis/survival in NPC patients and correlated with clinical staging. |
| Description: |
CDR1as is up-regulated in NPC tissues and cell lines and promotes NPC growth and glycolytic metabolism. Mechanistically, CDR1as acts as a ceRNA sponge for miR-7-5p, thereby increasing E2F3 expression, which supports proliferation and tumor growth in xenografts. |
| Confidence score: |
0.7396 |